1 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow REGN13089-M404-M2980: new trials by email Literature Review of REGN13089-M404-M2980 trials Research Report on REGN13089-M404-M2980
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Stomach Neoplasms (1) · Uveal Melanoma (1)